With a 10% Dividend Hike, Amgen Stock Deserves Investor Attention
A Biotech Stock for Income Investors?
In a crashing market, I’d like to read something cheerful. One of things that could lighten up the mood, especially for dividend investors, is an announcement from Amgen, Inc. (NASDAQ:AMGN).
Amgen is a biopharmaceutical company headquartered in Thousand Oaks, California. Last Friday, the company announced that its board of directors has approved a quarterly dividend rate of $1.45 per share, starting with the first quarter of 2019. This represented a 10% increase from the company’s previous quarterly dividend payment of $1.32 per share. (Source: “Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend,” Amgen, Inc., December 7, 2018.)
For the most part, biotech stocks aren’t the go-to choice for income investors. While the broader healthcare sector has produced many dividend giants, biotech is known for its uncertainty. For instance, if the future of a biotech company depends on the results of a certain clinical trial, it’s probably not the best choice for investors who are looking to earn a steady stream of dividend income.
The good news is, AMGN is not the average biotech stock. In fact, with a market capitalization of over $120.0 billion, Amgen, Inc. is one of the largest biotech companies in the world.
In particular, the company does have a recurring business model. For instance, the two top selling products at Amgen, “Enbrel” and “Neulasta,” each generate billions of dollars of revenue a year.
With a recurring business model, Amgen can set up a regular dividend policy.
And the amount it pays out has only been going up.
Amgen, Inc. Is a Top Dividend Growth Stock
You see, Amgen stock started paying quarterly dividends in 2011. Its initial quarterly dividend rate was $0.28 per share.
Since then, the company has raised the amount every single year. With the latest dividend hike to $1.45 per share, AMGN stock’s payout has grown by a staggering 418%. (Source: “Dividend Information,” Amgen, Inc., last accessed December 10, 2018.)
If you are wondering whether these dividend increases were a bit too aggressive, a look at the company’s financials should be reassuring.
In the most recent quarter, Amgen, Inc. generated adjusted earnings of $3.69 per share, representing a 13% increase year-over-year. Moreover, the amount covered the company’s dividend payment of $1.32 per share for the quarter more than twice over. (Source: “Amgen Reports Third Quarter 2018 Financial Results,” Amgen, Inc., October 30, 2018.)
At the same time, management also raised their guidance. Amgen is now projected to generate adjusted earnings of $14.00 to $14.25 per share for full-year 2018. This would easily cover AMGN stock’s total dividends of $5.28 per share paid for the year.
Amgen Stock Returns Cash to Investors
At the end of the day, I should point out that one of the reasons why Amgen can deliver impressive earnings-per-share growth is its lower share count over time: the company has been buying back its shares.
Just like dividends, stock buybacks represent a way for companies to return cash to investors. In just the third quarter alone. Amgen repurchased 8.7 million shares for $1.7 billion. And by the end of the quarter, Amgen still had $3.7 billion remaining under its stock buyback authorization.
A buyback program, like the one Amgen is pursuing right now, lowers the number of shares outstanding. Therefore, it allows each existing shareholder to own a slightly larger portion of the company.
Trading at $194.09 apiece, AMGN stock offers an annual yield of around three percent.
You can find higher-yielding stocks in the market. But thanks to the company’s continued dividend growth, AMGN stock investors will likely collect much higher yield-on-cost a few years down the road.
Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners
Sign up to receive our FREE Income Investors newsletter along with our special offers and get our FREE report:
5 Dividend Stocks to Own Forever
This is an entirely free service. No credit card required. You can opt-out at anytime.
We hate spam as much as you do.